TY - JOUR
T1 - Review on flavivirus vaccine development
T2 - Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand
AU - Hombach, J.
AU - Barrett, A. D.
AU - Cardosa, M. J.
AU - Deubel, V.
AU - Guzman, M.
AU - Kurane, I.
AU - Roehrig, J. T.
AU - Sabchareon, A.
AU - Kieny, M. P.
N1 - Funding Information:
Dr. J. Jacobson concluded the session on JE by presenting the newly established JE program at the Program for Appropriate Technology in Health (PATH) [16] . The JE program has a 5-year plan and is funded by a grant by the Bill & Melinda Gates Foundation. The program has identified four major goals. (1) Improve disease surveillance, including improved diagnostics, (2) advance an improved vaccine, (3) introduce and integrate the vaccine in routine immunization programmes, and (4) advocate and promote JE control, especially immunization. In close co-ordination with government health authorities and WHO, the program aims at demonstrating its activities in selected countries, including those which are using current vaccine and others which so far have not been using JE vaccine.
PY - 2005/4/15
Y1 - 2005/4/15
N2 - In light of the continuous spread of human pathogenic flaviviruses, in particular the mosquito-transmitted species, vaccine development remains a high priority on the public health agenda. On 26-27 April 2004, a conference was held in Bangkok, Thailand, to review current status of flavivirus vaccine development and related issues, focussing on dengue (DEN) and Japanese encephalitis (JE). This event, co-sponsored by the World Health Organization (WHO) and the Thai Ministry of Public Health, reviewed the progress made with vaccine development, sero-epidemiological studies and other accompanying activities critical for vaccine development and vaccination. The considerable interest in and awareness of the flavivirus diseases and their prevention by public health decision makers, as well as the establishment of two dedicated programmes for dengue and Japanese encephalitis vaccine development raise hopes that new or improved vaccines will become available in the coming years.
AB - In light of the continuous spread of human pathogenic flaviviruses, in particular the mosquito-transmitted species, vaccine development remains a high priority on the public health agenda. On 26-27 April 2004, a conference was held in Bangkok, Thailand, to review current status of flavivirus vaccine development and related issues, focussing on dengue (DEN) and Japanese encephalitis (JE). This event, co-sponsored by the World Health Organization (WHO) and the Thai Ministry of Public Health, reviewed the progress made with vaccine development, sero-epidemiological studies and other accompanying activities critical for vaccine development and vaccination. The considerable interest in and awareness of the flavivirus diseases and their prevention by public health decision makers, as well as the establishment of two dedicated programmes for dengue and Japanese encephalitis vaccine development raise hopes that new or improved vaccines will become available in the coming years.
KW - Flavivirus vaccine
KW - Human pathogenic flaviviruses
KW - Sero-epidemiological studies
UR - http://www.scopus.com/inward/record.url?scp=15044359108&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=15044359108&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2004.11.040
DO - 10.1016/j.vaccine.2004.11.040
M3 - Article
C2 - 15841565
AN - SCOPUS:15044359108
SN - 0264-410X
VL - 23
SP - 2689
EP - 2695
JO - Vaccine
JF - Vaccine
IS - 21
ER -